Tamtam Try Tamtam free
Amgen logo

Amgen account plan

Developing innovative human therapeutics

At a glance

Amgen is a biotechnology company making biologic medicines and biosimilars, with $36,751 million of 2025 revenues and about 31,500 staff.

Amgen discovers, develops, manufactures and delivers medicines, mostly biologics, in cardiovascular, bone health, inflammation, rare disease and oncology, and sells its own biosimilars. It operates in one segment, human therapeutics, selling mainly in the United States and Europe and through affiliates and partners in Asia, Latin America and the Middle East. In 2025 total revenues were $36,751 million (+10%), operating income $9,080 million and net income $7,711 million. Amgen had approximately 31,500 staff members in over 50 countries at December 31, 2025, and manufactures mainly in Puerto Rico.

Business units

Strategic priorities

Grow through patent expirations
Amgen says it must grow sales from existing and new products to offset losses of exclusivity; six growth drivers (Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, Biosimilars) grew 26% in Q2 2026 and were nearly 70% of product sales.
MariTide in obesity
MariTide, designed for monthly dosing, has 9 ongoing and 3 planned Phase 3 studies, and 2026 capex of approximately $2.6 billion includes preparation for its launch.
Cardiometabolic portfolio
Repatha, olpasiran and MariTide are presented as a combined cardiometabolic set; the olpasiran OCEAN(a) outcome study enrolled 7,297 patients.
Manufacturing expansion in the U.S.
Amgen opened a drug-substance site in Holly Springs, North Carolina in January 2025, broke ground on a second one and announced expansions in New Albany, Ohio and Puerto Rico.
AI across the value chain
Amgen applies AI across discovery, development, manufacturing and access to medicines and recently established a frontier AI laboratory, bringing agentic workflows to discovery research.
Direct-to-patient access
AmgenNow offers a simplified lower-cost cash-pay option for Repatha and is being extended to other medicines.

Latest results

In Q2 2026 total revenues rose 10% to $10,054 million, with product sales up 9% on volume, led by Repatha, EVENITY, UPLIZNA, TEZSPIRE, IMDELLTRA and PAVBLU, while Prolia fell 32% and Otezla 21%. Operating income rose 32% to $3,514 million and net income 66% to $2,375 million ($4.37 per diluted share). H1 2026 revenues were $18,672 million (+8%). Amgen raised 2026 guidance to total revenues of $38.2 billion to $39.4 billion and non-GAAP EPS of $22.30 to $23.50.

Investments and deals

Capital projects
Capex was $1.9 billion in 2025, and full-year 2026 capital projects are estimated at approximately $2.6 billion, including MariTide launch preparation.
R&D spending
R&D was $7,272 million in 2025 (+22%), with $4,281 million on later-stage clinical programs; Q2 2026 R&D rose 7% to $1,868 million, mainly on MariTide.
Business development
Business development focuses on the four therapeutic areas, primarily smaller earlier-stage assets; 2026 guidance includes a $100 million upfront in Q3.
Debt and shareholder returns
Amgen retired $6.0 billion of debt in 2025, issued $4.0 billion of notes in H1 2026, raised the quarterly dividend 6% to $2.52, and plans buybacks not exceeding $3 billion in 2026.

Challenges and risks

Biosimilar and generic erosion
Prolia and XGEVA face accelerated erosion from denosumab biosimilars in 2026, and Otezla faces generics in certain European countries.
U.S. drug pricing policy
IRA Medicare price setting (ENBREL from 2026, Otezla from 2027), expanded 340B use, the MFN initiative and CMS's GENEROUS Model weigh on net prices; ENBREL net price fell 22% in Q2 2026.
IRS tax dispute
The IRS seeks approximately $3.6 billion plus interest for 2010-2012 and approximately $5.1 billion plus penalties for 2013-2015; a Tax Court decision is expected no earlier than late 2026 or early 2027.
Pipeline setbacks
The FDA asked for a voluntary withdrawal of TAVNEOS on January 16, 2026, bemarituzumab will not be filed in first-line gastric cancer, and olpasiran event accrual is lower than initial predictions.
Manufacturing concentration and supply chains
Commercial manufacturing is concentrated in Puerto Rico, and conflict in the Middle East has increased volatility in energy and transportation markets and disrupted supply chains.

What leadership says

“once again demonstrate our ability to grow through patent expirations and increased competition”

Robert A. Bradway, Chairman and Chief Executive Officer · Q2 2026 earnings call, 4 August 2026

“a year of disciplined data generation”

Robert A. Bradway, Chairman and Chief Executive Officer · Q4 and full-year 2025 earnings call, 3 February 2026, on 2026

“the bar is high at Amgen for obesity medicines”

James Bradner, EVP Research and Development · Q2 2026 earnings call, 4 August 2026, on stopping AMG 513

“the 2 labels really just don't compare”

Murdo Gordon, EVP Global Commercial Operations · Q2 2026 earnings call, 4 August 2026, on oral PCSK9 competition for Repatha

Where a supplier can help

Launch readiness for MariTide
Tied to the MariTide priority and the approximately $2.6 billion capex plan: manufacturing capacity, device assembly and supply chain partners fit launch preparation.
Clinical trial operations
Tied to the growing later-stage R&D spend: CROs, trial technology and patient recruitment support the many Phase 3 programmes in obesity, cardiovascular and immunology.
AI and data for R&D
Tied to the AI priority: data platforms and AI tools fit the frontier AI laboratory and agentic workflows in discovery research.
Market access and direct-to-patient
Tied to the pricing challenge and AmgenNow: patient support, pricing analytics and cash-pay channel services help offset net price pressure.
Supply chain resilience
Tied to the manufacturing concentration challenge: logistics and supply risk tools address disruption and the concentration in Puerto Rico.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Amgen?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Amgen

What does Amgen do?

Amgen discovers, develops, manufactures and sells medicines, mostly biologics, for cardiovascular disease, osteoporosis, inflammation, rare diseases and cancer, and sells its own biosimilars.

What is Amgen's revenue?

Total revenues were $36,751 million in 2025, up 10%. Amgen guides 2026 total revenues of $38.2 billion to $39.4 billion.

How many employees does Amgen have?

Amgen had approximately 31,500 staff members in over 50 countries at December 31, 2025.

Who leads Amgen?

Robert A. Bradway is Chairman and CEO. Thomas Dittrich succeeds Peter Griffith as CFO, and James Bradner leads R&D.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)